Trade Replimune - REPL CFD

Replimune Company profile

About Replimune Group Inc

Replimune Group, Inc. is a clinical-stage biotechnology company. The Company is engaged in the field of oncolytic immunotherapy to treat the cancer patients. The Company applies its Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The Company is focused on developing a pipeline of oncolytic immunotherapy product candidates to provide clinical benefits to cancer patients. Its product candidates include RP1 (vusolimogene oderparepvec), RP2, and RP3. The Company is focused on Phase 2 clinical trials with its lead product candidate, RP1, in approximately 240 patients with a range of solid tumors.

Financial summary

BRIEF: For the nine months ended 31 December 2021, Replimune Group Inc revenues was not reported. Net loss increased 45% to $86.3M. Higher net loss reflects Research and development increase of 41% to $49.7M (expense), Stock-based Compensation in SGA increase from $4.6M to $12M (expense), General and administrative increase of 38% to $16.1M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.34 to -$1.66.